Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.
Press releases published on May 24, 2025
Digital Evolution Institute Showcases Artist Justin Wadlington at NASDAQ in May 2025
EIN Presswire
·
May 24, 2025
The Future of Tech-Savvy Boards Conference Adds a Dimension of Aesthetic Intelligence NEW YORK, NY, UNITED STATES, May 24, 2025 /EINPresswire.com/ -- The Digital Evolution Institute, a leading voice in future-forward technology and innovation, proudly …
New Comprehensive Rodent Models Developed by Creative Biolabs Aim to Improve Disease Research
EIN Presswire
·
May 24, 2025
Creative Biolabs has recently expanded its research in non-transgenic rodent models to meet the growing diversity of non-clinical study needs. SHIRLEY, NY, UNITED STATES, May 24, 2025 /EINPresswire.com/ -- Creative Biolabs has recently expanded its …
Creative Diagnostics Advances Influenza Antiviral Drug Discovery with Comprehensive Screening and Evaluation Services
EIN Presswire
·
May 24, 2025
Creative Diagnostics has announced its comprehensive suite of services for Influenza Antiviral Drug Screening and Evaluation. NEW YORK, NY, UNITED STATES, May 24, 2025 /EINPresswire.com/ -- As an expert in providing solutions to assist virology and …
Creative Diagnostics Launches Highly Sensitive T7 RNA Polymerase ELISA Kits for Biopharmaceutical Impurity Detection
EIN Presswire
·
May 24, 2025
Creative Diagnostics has released T7 RNA Polymerase ELISA Kits for the detection and quantitative determination of T7 RNA Polymerase. NEW YORK, NY, UNITED STATES, May 24, 2025 /EINPresswire.com/ -- Creative Diagnostics, a leading manufacturer and …
SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN
GlobeNewswire
·
May 24, 2025
– im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN – – die Entscheidung der Europäischen Kommission wird für das dritte Quartal 2025 erwartet – STAMFORD, Conn., …
SpringWorks Therapeutics recibe un dictamen positivo del CHMP para el uso de mirdametinib en el tratamiento de la NF1-NP en pacientes adultos y pediátricos
GlobeNewswire
·
May 24, 2025
– Si se aprueba, se espera que el mirdametinib sea la primera y única terapia autorizada para el tratamiento de la NF1-NP en la Unión Europea, tanto para adultos como para niños – – Decisión de la Comisión Europea prevista en el tercer trimestre de 2025 – …
SpringWorks Therapeutics reçoit un avis favorable du CMUH pour l’utilisation du mirdamétinib pour le traitement des patients adultes et pédiatriques atteints de NF1-PN
GlobeNewswire
·
May 24, 2025
– S’il est approuvé, le mirdamétinib devrait être le premier et unique traitement dans l’Union européenne à bénéficier d’une autorisation de mise sur le marché pour les adultes et les enfants atteints de NF1-PN – – La décision de la Commission européenne …
SpringWorks Therapeutics: CHMP valuta positivamente Mirdametinib per il trattamento di pazienti adulti e pediatrici affetti da NF1-PN
GlobeNewswire
·
May 24, 2025
– Se approvato, mirdametinib sarà la prima e unica terapia nell'Unione europea a ottenere l'autorizzazione all'immissione in commercio sia per gli adulti che per i bambini affetti da NF1-PN – – La decisione della Commissione europea è prevista nel terzo …
SpringWorks Therapeutics krijgt positief advies van de CHMP voor Mirdametinib voor de behandeling van volwassen en pediatrische patiënten met NF1-PN
GlobeNewswire
·
May 24, 2025
- Als mirdametinib wordt goedgekeurd, zal het naar verwachting de eerste en enige therapie in de Europese Unie zijn met een handelsvergunning voor zowel volwassenen als kinderen met NF1-PN - - Besluit van de Europese Commissie wordt verwacht in het derde …
GoHealth, Inc. 投資者消息：若您因 GoHealth, Inc. (NASDAQ: GOCO) 蒙受損失，請聯絡 Rosen Law Firm 了解您的權益
GlobeNewswire
·
May 24, 2025
紐約, May 25, 2025 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 宣布代表 GoHealth, Inc. (NASDAQ: GOCO) 的股東，調查 GoHealth 可能向投資公眾發佈重大誤導性業務訊息並就此引發的潛在證券索賠。 影響：若您購買了 GoHealth 證券，您可能有權獲得賠償，並透過勝訴收費安排，免去任何自付費用或開支。 Rosen Law Firm 正準備提出集體訴訟，期望為投資者討回損失。 …
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Krispy Kreme, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DNUT
GlobeNewswire
·
May 24, 2025
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Krispy Kreme, Inc. (NASDAQ: DNUT) between February 25, 2025 and May 7 …
TechTarget, Inc. 投資者新聞：如果您在 TechTarget, Inc.（NASDAQ: TTGT）蒙受損失，我們鼓勵您聯絡 Rosen Law Firm 以瞭解您的權利
GlobeNewswire
·
May 24, 2025
紐約, May 25, 2025 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律所 Rosen Law Firm 宣布代表 TechTarget, Inc.（NASDAQ: TTGT）股東調查潛在證券索賠。此事起因為 TechTarget 被控可能向投資大眾發布了嚴重誤導性商務資訊。 影響：如果您購買了 TechTarget 證券，您可能有權獲得賠償，並且根據後酬約定而無需支付任何自付費用或成本。 Rosen Law Firm 在準備一項針對投資者損失進行追討的集體訴訟。 …
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TASK, RDFN, DNB on Behalf of Shareholders
GlobeNewswire
·
May 24, 2025
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: …
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGMA, VIGL, STRR on Behalf of Shareholders
GlobeNewswire
·
May 24, 2025
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: …
TechTarget, Inc. Investor News: If You Have Suffered Losses in TechTarget, Inc. (NASDAQ: TTGT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire
·
May 24, 2025
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TechTarget, Inc. (NASDAQ: TTGT) resulting from allegations that …
GoHealth, Inc. Investor News: If You Have Suffered Losses in GoHealth, Inc. (NASDAQ: GOCO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire
·
May 24, 2025
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GoHealth, Inc. (NASDAQ: GOCO) resulting from allegations that GoHealth …
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
GlobeNewswire
·
May 24, 2025
NYC, May 24, 2025 (GLOBE NEWSWIRE) -- NEW YORK, May 24, 2025 / GlobeNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde …
TechTarget, Inc. Investor News: If You Have Suffered Losses in TechTarget, Inc. (NASDAQ: TTGT), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
GlobeNewswire
·
May 24, 2025
NEW YORK, May 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TechTarget, Inc. (NASDAQ: TTGT) resulting from allegations that …
Best Smart Bird Feeder 2025: Happy Birdy Review – Top Bird Feeder with AI Camera for Backyard Bird Watching
GlobeNewswire
·
May 24, 2025
Akron, OH, May 24, 2025 (GLOBE NEWSWIRE) -- Introduction - Smart Bird Feeder In recent years, backyard bird watching has evolved from a quiet pastime into an interactive experience, thanks to the arrival of smart bird feeders. The Happy Birdy Smart Feeder …
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
GlobeNewswire
·
May 24, 2025
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily …